# US 2024/0002802 A1 · Modified nk-92 cells for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002802 A1
- Document ID: US20240002802A1
- Status: Published application
- Kind: A1
- Application number: 18/463,213
- Filed: 2023-09-07
- Published: 2024-01-04
- Earliest claimed: 2015-06-10
- Assignees: ImmunityBio, Inc.
- Applicants: ImmunityBio, Inc.
- Inventors: Tien Lee
- Web page: https://patentgrep.com/patent/US20240002802A1

## CPC

- C07K 14/54: Interleukins [IL]
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 40/00: Cellular immunotherapy (medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4211: {CD19 or B4}
- A61K 40/4224: {Molecules with a "CD" designation not provided for elsewhere}
- A61K 40/4261: {Proteoglycans, e.g. glypican, brevican or CSPG4}
- A61P 35/00: Antineoplastic agents
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2803: {against the immunoglobulin superfamily}
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- A61K 2039/505: {comprising antibodies}
- A61K 2239/13: Antibody-based
- A61K 2239/28: Expressing multiple CARs, TCRs or antigens
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/04: containing an ER retention signal such as a C-terminal HDEL motif
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2510/00: Genetically modified cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are NK-92 cells expressing at least one CAR and at least one Fc receptor. Also provided are methods of treatment of a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer, comprising administering to the patient NK-92-Fc-CAR.

## Claims

### Claim 1

A method of treating a cancer in a patient in need thereof, the method comprising:
administering to the patient an effective amount of an NK-92 cell line comprising modified NK-92 cells;
wherein the modified NK-92 cells are each modified to express and display on the cell surface of the modified NK-92 cells at least one Fc receptor and at least one chimeric antigen receptor (CAR), wherein the CAR is capable of binding CD33 or CSPG-4 expressed on a surface of a cancer cell;
wherein the CAR has a scFv segment that is coupled via a hinge portion to a transmembrane domain and an intracellular signaling domain; and
wherein the scFv segment has the amino acid sequence of amino acids 21-266 of SEQ ID NO:11 or amino acids 21-281 SEQ ID NO:13.

### Claim 2 (depends on 1)

The method of claim 1, wherein the CAR further comprises a signal peptide coupled to the N-terminus of the scFv segment, and wherein the signal peptide has the amino acid sequence of amino acids 1-20 of SEQ ID NO:11 or SEQ ID NO:13.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cancer is acute myeloid leukemia, breast cancer, a sarcoma, a neuroblastoma, or a mesothelioma.

### Claim 4 (depends on 1)

The method of claim 1, wherein the hinge portion has the amino acid sequence of amino acids 267-327 of SEQ ID NO:11 or amino acids 284-347 SEQ ID NO:13.

### Claim 5 (depends on 1)

The method of claim 1, wherein the transmembrane domain is a CD3zeta transmembrane domain.

### Claim 6 (depends on 1)

The method of claim 1, wherein the intracellular signaling domain is a CD3zeta intracellular signaling domain.

### Claim 7 (depends on 1)

The method of claim 1, wherein the CAR has the amino acid sequence of SEQ ID NO:11.

### Claim 8 (depends on 1)

The method of claim 1, wherein the CAR is encoded by the nucleic acid sequence of SEQ ID NO:10.

### Claim 9 (depends on 1)

The method of claim 1, wherein the CAR has the amino acid sequence of SEQ ID NO:13.

### Claim 10 (depends on 1)

The method of claim 1, wherein the CAR is encoded by the nucleic acid sequence of SEQ ID NO:12.

### Claim 11 (depends on 1)

The method of claim 1, wherein the Fc receptor is FcγRIII-A (CD16) or a CD16 polypeptide having a valine at position 158 of the mature form of the CD16.

### Claim 12 (depends on 1)

The method of claim 1, wherein the Fc receptor has the amino acid sequence of SEQ ID NO:2.

### Claim 13 (depends on 1)

The method of claim 1, wherein the modified NK-92 cells are modified to express a cytokine.

### Claim 14 (depends on 13)

The method of claim 13, wherein the cytokine is IL-2 or IL15, optionally modified to target the endoplasmic reticulum.

### Claim 15 (depends on 1)

The method of claim 1, wherein the effective amount is at least about 1×108 cells.

### Claim 16

A modified NK92-cell, wherein
(1) the modified NK-92 cells are modified to each express at least one Fc receptor and at least one chimeric antigen receptor (CAR), such that the at least one Fc receptor and the at least one CAR are displayed on the cell surface of the modified NK-92 cells;
(2) the CAR has a scFv segment that is coupled via a hinge portion to a transmembrane domain and an intracellular signaling domain, and wherein the CAR is capable of binding CD33 or CSPG-4 expressed on a surface of a cancer cell; and
(3) the scFv segment has the amino acid sequence of amino acids 21-266 of SEQ ID NO:11 or amino acids 21-281 SEQ ID NO:13.

### Claim 17 (depends on 16)

The modified NK92-cell of claim 16, wherein the CAR is encoded by the nucleic acid sequence of SEQ ID NO:10 or wherein the CAR is encoded by the nucleic acid sequence of SEQ ID NO:12.

### Claim 18 (depends on 16)

The modified NK92-cell of claim 16, wherein the transmembrane domain is a CD3zeta transmembrane domain, and/or wherein the intracellular signaling domain is a CD3zeta intracellular signaling domain.

### Claim 19 (depends on 16)

The modified NK92-cell of claim 16, wherein the modified NK-92 cells are modified to express a cytokine.

### Claim 20 (depends on 16)

The modified NK92-cell of claim 16, wherein the Fc receptor is FcγRIII-A (CD16) or a CD16 polypeptide having a valine at position 158 of the mature form of the CD16.
